Seaport Therapeutics Welcomes Lauren White as New CFO
In a significant move for the biopharmaceutical landscape, Seaport Therapeutics has proudly announced the appointment of Lauren White as its Chief Financial Officer. With a rich history in biotech finance, White joins the innovative team at Seaport during a pivotal time in its journey.
Lauren White's Impressive Background
White brings over 22 years of extensive experience in corporate finance, strategic partnerships, and investor relations. Before taking on this new role, she served as CFO at ImmunoGen, where she played a crucial role during its acquisition by AbbVie, valued at $10.1 billion. This experience showcases her capabilities in navigating financial landscapes and aligning strategies for corporate growth.
Key Achievements at ImmunoGen
During her tenure at ImmunoGen, White was instrumental in the commercial launch of ELAHERE, a pioneering antibody-drug conjugate (ADC) aimed at treating platinum-resistant ovarian cancer. Her leadership not only drove financial success but also enabled the organization to make considerable advancements in the realm of oncology therapeutics.
Vision for Seaport Therapeutics
Daphne Zohar, Founder and CEO of Seaport, expressed excitement over White's appointment, emphasizing how her deep expertise will contribute to furthering the development of therapeutics for anxiety, depression, and other neuropsychiatric disorders. The addition of White aligns with Seaport's mission to innovate and deliver essential medicines.
Building on Proven Strategies
This new leadership comes as Seaport Therapeutics is dedicated to advancing cutting-edge neuropsychiatric medicines. The company utilizes a proprietary Glyph technology platform, uniquely designed to improve bioavailability and minimize side effects, thereby enhancing the therapeutic experience for patients.
Expanding Horizons with Experienced Leadership
White’s prior experience includes significant roles at Novartis, where she served as Global Head of Financial Planning and Analysis, as well as other strategy-focused positions at Boston Consulting Group and General Electric. Her diverse skill set is expected to be invaluable as Seaport moves forward with its clinical initiatives.
Future Plans for Neuropsychiatric Treatment
In her own words, White expressed her enthusiasm, stating, "I am excited to join the outstanding team at Seaport during this important stage of development." Her presence at Seaport is poised to amplify efforts around capital financing strategies, accounting, and investor relations, which are essential for scaling operations and driving clinical advancement.
About Seaport Therapeutics
Seaport Therapeutics stands at the forefront of clinical-stage research, specializing in the design and development of novel therapies that address severe neuropsychiatric conditions. Their innovative approach focuses on leveraging clinically validated mechanisms and overcoming past limitations through advanced technology. With a team that has a history of discovering and developing impactful therapeutics, Seaport aims to bring forth solutions that transform patients’ lives.
About PureTech Health
PureTech Health is a clinical-stage biotherapeutics company committed to creating transformative therapies for patients suffering from serious diseases. The company continues to expand its focus through a combination of internal advancements and collaboration with its Founded Entities, harnessing a portfolio that includes 29 therapeutic candidates across various stages of clinical development.
Frequently Asked Questions
What position has Lauren White been appointed to?
Lauren White has been named the Chief Financial Officer of Seaport Therapeutics.
What notable experience does Lauren White bring to Seaport?
White has over 22 years of experience in biotech finance, most recently serving as CFO at ImmunoGen.
What is the focus of Seaport Therapeutics?
Seaport Therapeutics is focused on advancing novel neuropsychiatric medicines to address significant patient needs.
How has PureTech Health contributed to the biopharmaceutical field?
PureTech Health leverages innovative strategies to develop a broad pipeline of therapeutics, impacting diseases with high unmet needs.
What technology does Seaport utilize for its therapeutics?
Seaport employs a proprietary Glyph technology platform aimed at improving bioavailability and reducing side effects of therapies.
